© 2017 Pharmstandard Ventures
Argos Therapeutics
(NASDAQ:ARGS)
Durham, NC, USA
Year of Investment: 2013
(NASDAQ:ARGS)
Durham, NC, USA
Year of Investment: 2013
Strategic Deal with Pharmstandard in July, 2013
IPO in February, 2014
Strategic Deal with Lummy in April, 2015
IPO in February, 2014
Strategic Deal with Lummy in April, 2015
Argos Therapeutics
(NASDAQ:ARGS)
Durham, NC, USA
Year of Investment: 2013
(NASDAQ:ARGS)
Durham, NC, USA
Year of Investment: 2013
Strategic Deal with Pharmstandard in July, 2013
IPO in February, 2014
Strategic Deal with Lummy in April, 2015
IPO in February, 2014
Strategic Deal with Lummy in April, 2015
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos most advanced product candidate AGS-003 is progressing in a pivotal Phase 3 study for the treatment of metastatic renal cell carcinoma(mRCC).
For more information, please visit:
www.argostherapeutics.com
For more information, please visit:
www.argostherapeutics.com
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally